All News

Found 318 articles

• Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill

  4/13/2022

  Scilex Holding Company, a nearly 100% majority-owned subsidiary of Sorrento Therapeutics, Inc. announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors.

• Y-mAbs Announces Presentation of SADA Technology at AACR

  4/8/2022

  Y-mAbs Therapeutics, Inc. announced that a poster presentation featuring preclinical data from its GD2 SADA construct will be presented at the AACR Annual Meeting 2022, which takes place in New Orleans, Louisiana from April 8-13, 2022.

• Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA

  4/1/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that on March 31, 2022, the Company completed the resubmission of its Biologics License Application (“BLA”) for 131 I-omburtamab (“omburtamab”) to the FDA.

• Biopharmaceutical CMO and CRO Market Expected to Gain 7.4% CAGR by 2030

  4/1/2022

  The global biopharmaceutical CMO and CRO market size is set to grow exponentially. It was valued at USD 31.17billion back in 2021 and is predicted to hit around USD 59.13 billion by 2030, according to Precedence Research.

• Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology

  3/29/2022

  Biosion, Inc., a global R&D stage biotechnology company, today announced that Biosion and Pyxis Oncology (NASDAQ: PYXS) have entered into an agreement under which Pyxis Oncology will be granted an exclusive license to develop and commercialize Biosion's anti-Siglec-15 monoclonal antibody, BSI-060T (now referred to as PYX-106), world-wide, excluding Greater China.

• Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform

  3/24/2022

  Glycotope GmbH, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, announces that is has completed a re-focusing of its strategy to better deliver value from its powerful, proprietary glycobiology-informed technology platform.

• Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022

  3/22/2022

  Pyxis Oncology, Inc. announced it will host a conference call and live webcast on Tuesday, March 29, 2022 at 8:00 a.m. ET to discuss recent corporate updates.

• Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody

  3/10/2022

  Tiziana Life Sciences reported positive clinical data in a patient with Secondary Progressive Multiple Sclerosis, following completion of six months of treatment with intranasally administered foralumab, at the Brigham and Women’s Hospital, Harvard University, Boston, MA.

• Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

  3/1/2022

  Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2021.

• New Data Further Reinforce Efficacy Of Tezspire™ (Tezepelumab-Ekko) In A Broad Population Of Severe Asthma Patients

  2/26/2022

  Amgen announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed TEZSPIRE™ demonstrated reductions in the annualized asthma exacerbation rate across biomarker subgroups of patients with severe asthma.

• Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments

  2/24/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), today reported financial results for the fourth quarter and the full year ended December 31, 2021 and provided recent corporate highlights.

• Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022

  2/17/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the year ended December 31, 2021 on Thursday, February 24, 2022, after the close of the U.S. financial markets.

• Genmab Publishes 2021 Annual Report

  2/16/2022

  Genmab A/S announced the publication of its Annual Report for 2021.

• 

  Biogen Officially Weighs in On Medicare Draft Guidance for Aduhelm

  2/11/2022

  ​CMS issued a draft decision for Biogen’s Alzheimer’s drug and said it would only cover the cost of Aduhelm and any required scans “if they are enrolled in qualifying clinical trials.”

• Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab

  2/11/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it recently completed a Pre-Biologics License Application (“pre-BLA”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential pathway for FDA approval of omburtamab for the treatment of patients with CNS/leptomeningeal metastases from neuroblastoma.

• Unchained Labs adds biopharma vet Laura Hamill to the Board

  2/9/2022

  Unchained Labs announced the addition of Laura Hamill to its Board today.

• Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021

  1/25/2022

  Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab) as reported by Johnson & Johnson were USD 6,023 million in 2021.

• TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA

  1/13/2022

  Amgen (NASDAQ:AMGN) and AstraZeneca today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the U.S. TEZSPIRE was approved by the U.S. Food and Drug Administration (FDA) on Dec. 17, 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

• Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development

  1/5/2022

  Repare Therapeutics Inc. today announced the appointment of Philip Herman as its EVP Commercial & New Product Development.

• Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

  1/5/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that its Chief Executive Officer, Dr. Claus Moller, MD, Ph.D., will provide an overview and update on the Company's business at the virtual 40th Annual J.P. Morgan Healthcare Conference.